Miguel A Escobar MD

PubMed

• Assessing factor consumption and bleeding outcomes of prophylaxis with 3 commonly prescribed factor IX products for hemophilia B: A retrospective patient medical recor...
  Miguel Escobar, Songkai Yan, Ying Yang, Douglass Drelich, Xiang Zhang
  Journal of Managed Care & Specialty Pharmacy. 2025-11-14
• Correction: A scan of pleiotropic immune mediated disease genes identifies novel determinants of baseline FVIII inhibitor status in hemophilia A.
  Marcio A Almeida, Vincent P Diego, Kevin R Viel, Bernadette W Luu, Karin Haack
  Genes and Immunity. 2025-09-25
• Chromogenic vs one-stage assay to diagnose women and girls with hemophilia A-mapping global approaches and assessing challenges: communication from the SSCs of the ISTH.
  Lakshmi Srivaths, Joanna Larson, Karin Fijnvandraat, Jesus Ardila, Miguel Escobar
  Journal of Thrombosis and Haemostasis. 2025-08-01

Journal Articles

• Switching patients in the age of long-acting recombinant products?  
  Escobar, M. Santagostino E, Mancuso ME, Coppens M, et al., Expert Review of Hematology, 1/1/2019
• Identification and characterization of novel mutations implicated in congenital fibrinogen disorders  
  Smith N, Bornokova L, Noetzli L, Guglielmone H, Minoldo S, Backos D, Jacobson L, Thornburn C, Escobar M, et al., Research and Practice in Thrombosis and Haemostasis, 1/1/2018
• cross-sectional analysis of cardiovascular disease in the hemophilia population  
  Sood SL, Cheng D, Ragni M, Kessler CM, Quon D, Shapiro AD, Key NS, Manco-Johnson MJ, Cuker A, Kempton C, Wang T, Eyster ME, Kuriakose P, von Drygalski A, Gill JC, Whee..., Blood Advances, 1/1/2018
• Unnecessary use of inferior vena cava filters: a teachable moment  
  Goswamy RV, Maiti A, Escobar MA, JAMA Intern Med, 1/1/2017
• Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: A review of clinical studie...  
  Young G, Escobar MA, Pipe SW, Cooper DL, Am J Hematol, 1/1/2017
• Major and minor classifications for surgery in people with hemophilia: A literature review  
  Solimeno LP, Escobar MA, Krassova S, Seremetis S, Clin Appl Thromb Hemost., 1/1/2017
• Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX  
  Escobar MA, Tehranchi R, Karim A, Caliskan U, Chowdary P, et al., Haemophilia, 1/1/2017
• Providing hemostatic and blood conservation options for Jehovah�s witness patients in a large medical system  
  Bai, Y., Castillo, BS., Tchakarov, A., Escobar, MA., Cotton, BA., et al., Annals of Clinical & Laboratory Science, 1/1/2016
• Efficacy and safety of rVIII-SingleChain: results of a phase I/III multicenter clinical trial in severe hemophilia A  
  Mahlangu J, Kuliczkowski K, Abdul Karim F, Stasyshyn O, Kosinova MV, Lepatan LM, Skotnicki A, Boggio LN, Klamroth R, Oldenburg J, Hellman A, Santagostino E, Baker RI, ..., Blood, 1/1/2016
• Antifactor Xa levels vs activated partial thromboplastin time for monitoring unfractionated heparin A pilot study  
  Samuel S, Allison TA, Sharaf S, Yau G, Ranjbar G, Mckaig N, Nguyen A, Escobar M, and Choi HA, Journal of Clinical Pharmacy and Therapeutics, 1/1/2016
• Experience of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency undergoing surgery  
  Escobar MA, G. Auerswald, S. Austin, J. N. Huang, M. Norton and C. M. Millar, Haemophilia, 1/1/2016
• Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital hemophilia with inhibitors  
  Santagostino E, Escobar M, Ozelo M, Solimeno L, et al., Blood Reviews, 1/1/2015
• Characteristics of hemophilia patients with factor VIII inhibitors detected by prospective screening  
  Miller CH, Rice AS, Boylan B, Payne AB, Kelly FM, Escobar MA, et al., Am J Hematol, 1/1/2015
• Optimising musculoskeletal care for patients with haemophilia  
  Carcao M, Hilliard P, Escobar M, Solimeno L, Mahlangu J, Santagostino E, Eur J Haematol, 1/1/2015
• Advances in the treatment of inherited coagulation disorders  
  Escobar, M.A., Haemophilia, 1/1/2013
• Hemophilia A and hemophilia B: focus on arthropathy and variables affecting bleeding severity and prophylaxis  
  Escobar, M.A., Sallah, S., Journal of Thrombosis and Haemostasis, 1/1/2013
• Bleeding in the Patient with a Malignancy  
  Escobar, M.A., Cancer, 1/1/2012
• Total joint replacement in advanced haemophilic arthropathy: A review of outcome, complications, impact of HIV and Inhibitors  
  Rodriguez-Merchan, EC, Rodriguez, NI, Escobar, M.A., Journal of Clinical Rheumatology & Musculoskeletal Medicine, 1/1/2012
• Utilization Patterns and Associated Costs of Factor Assistance Programs among Persons with Hemophilia: A Single Institution Review  
  Khleif, A., Rodriguez, N., Brown, D., Escobar, M.A., Haemophilia, 1/1/2012
• Best Practices for the Multidisciplinary Management of Patients with Hemophilia with Inhibitors Undergoing Surgery in the United States  
  Escobar, M.A, Maahs, J, Hellman, E, Donkin, J, Forsyth, A, Hroma, N, et al., Haemophilia, 1/1/2012
• Multiple Co-morbid Conditions Among Middle-aged and Elderly Hemophilia Patients: Prevalence Estimates and Implications for Future Care  
  Khleif, A., Rodriguez, N., Brown, D., and Escobar, M.A., Journal of Aging Research, 1/1/2011
• In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study  
  Kempton CL, Soucie FM, Miller CH, Hooper C, Escobar M.A., Cohen AJ, Key NS, Thompson AR, and Abshire TC, J Thromb Haemost, 1/1/2010
• Back to the future: covalent epitope-based HIV vaccine development  
  Paul, S., Planque, S., Nishiyama, Y., Escobar, M., Hanson, C., Expert Review Vaccines, 1/1/2010
• Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120�CD4-binding site from long-term survivors of HIV infection  
  Planque, S., Salas, M., Mitsuda, Y., Sienczyk, M., Escobar, M.A., et.al., AIDS, 1/1/2010
• Health Economics in Haemophilia: A review from the clinician�s perspective  
  Escobar, M.A., Haemophilia, 1/1/2010
• Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression  
  Vaklavas, C., Otelo-Rafiq, EP., Lovy, J., Escobar, M.A. and Tsimberidou, AM., Virology Journal, 1/1/2010
• Covalent inactivation of Factor VIII antibodies by an electrophilic FVIII analog  
  Planque, S., Escobar, M.A., Smith, KC., Taguchi, H., Nishiyama, Y., Donnachie, E., Pratt, KP., Paul, S., Journal of Biological Chemistry, 1/1/2008
• An Acute Intracerebral Vein Thromboses in AIDS A Case Report  
  Marcos, L.A., Majid, R., Hamzeh, Nabeel, Mehta Niraj, Escobar, M.A., International Journal of STD and AIDS, 1/1/2008
• Thrombelastograph and ROTEM guided Factor VIIa Therapy in a Surgical Patient with Severe Hemophilia and Factor VIII Inhibitor  
  Pivalizza, E.G., Escobar, M.A., Anesthesia & Analgesia, 1/1/2008
• Anticoagulation After Cardioembolic Stroke: To Bridge or Not to Bridge?  
  Hallevi, H., Albright, K.C., Martin-Schild, S., Barreto, A.D., Savitz, S.I., Escobar, M.A., Gonzales, N.R., Noser, E.A., Illoh, Kachi, Grotta, J.C.; On behalf of the V..., Archives of Neurology, 1/1/2008
• The Effect of Activated Factor VII for Intracerebral Hemorrhage Beyond Three Hours vs Within Three Hours  
  Hallevi, H., Gonzales, N.R., Barreto, A.D., Martin-Schild, S., Albright, K.C., Noser, E.A., Illoh, K., Khaja, A.M., Allison, T., Escobar, M.A., Shaltoni, H.M., and Gro..., Stroke, 1/1/2008
• Characterization of gp120 hydrolysis by IgA antibodies from humans without HIV infection  
  Planque, S., Mitsuda, Y., Taguchi, H., Salas, M., Morris, M.-K., Nishiyama, Y., Kyle, R., Okhuysen, P., Escobar, M.A., Hunter, R., Sheppard, H.W., Hanson, C., Paul, S., AIDS Research and Human Retroviruses, 1/1/2007
• The Role of Data and Safety Monitoring in Acute Trauma Resuscitation Research  
  Champion H.R, Fingerhut, A., Escobar, M.A., Weiskopf, R, Journal of the American College of Surgeons, 1/1/2007
• The Malmo International Brother Study (MIBS)-Genetic defects and inhibitor development in siblings with severe hemophilia A  
  Astermark, J., Oldenburg, J., Escobar, M.A., White, G.C., Berntorp, E. and the MIBS study group, Haematologica, 1/1/2005
• Endpoints in clinical trials involving hemostasis and bleeding  
  Escobar, M.A., Transfusion, 1/1/2005
• Hemophilia care in the 21st century and beyond  
  Kempton, L.K, Escobar, M.A., Roberts, H.R., Clinical Advances in Hematology & Oncology, 1/1/2004
• The use of recombinant factor VIIa in patients undergoing liver transplant  
  Escobar M.A., Hoots W.K., Transfusion Alternatives in Transfusion Medicine, 1/1/2003
• Recombinant Factor VIIa: The possibilities for monitoring  
  Escobar M.A., Transfusion Alternatives in Transfusion Medicine, 1/1/2003
• Treatment on demand � in vivo dose finding studies  
  Escobar, M.A., Haemophilia, 1/1/2003
• Delivery of Treatment for Haemophilia: Report of a joint WHO/WFH/ISTH meeting  
  Escobar, M., World Health Organization, 1/1/2002
• Red cell rosetting and erythrophagocytosis in adult Paroxysmal Cold Hemoglobinuria  
  Depcik-Smith, N.D., Escobar, M.A., Ma, A.D., Brecher, M.E., Transfusion, 1/1/2001
• Renal cell carcinoma  
  Godley, P.A., Escobar, M.A., Current Opinion in Oncology, 1/1/1998
• Concurrent mucosal Leishmaiasis and Pulmonary Tuberculosis  
  Escobar, M.A., Saravia, N.G, Weigle, K.A., Clinical Infectious Diseases, 1/1/1996
• A clinical prediction rule for American cutaneous leishmaniasis in Colombia  
  Weigle, K.A., Escobar, M.A., Arias, A.L., Martinez, F. Rojas, C.A., International Journal of Epidemiology, 1/1/1993
• American cutaneous and mucocutaneous leishmaniasis (tegumentary): A Diagnostic Challenge  
  Escobar, M.A., Martinez, F., Smith, S., Palma, G., Tropical Doctor, 1/1/1992
• Hemoculture of Leishmania (Viannia) braziliensis from two cases of mucosal leishmaniasis: re- examination of hematogeneous dissemination  
  Martinez, J.E., Arias, A.L., Escobar, M.A., Saravia, N.G., Transactions of the Royal Society of Tropical Medicine and Hygiene, 1/1/1992
• Hemoglobinopat�as en un grupo �tnico negro Colombiano  
  Escobar, M.A., Duque, H.E., Caicedo, C.H., Barco, H.Z., Colombia M�dica, 1/1/1988
• Join now to see all

Books/Book Chapters

• Management of Bleeding Patients 
  Chapter: Known bleeding disorders for surgery. 
  Escobar, M.A., Nguyen T.T., Montanez N.Editors: J. Teruya.SpringerEdition 2,2021
• Williams Hematology 
  Chapter: Hemophilia A and Hemophilia B 
  Escobar, MA and Reding M.Editors: Beutler E., et al..McGraw HillEdition 10,2021
• Consultative Hemostasis and Thrombosis 
  Chapter: Less common congenital disorders of hemostasis. 
  Escobar, MA.Editors: CS Kitchens, et al..W.B. Saunders CompanyEdition 4,2019
• The Core Topics of Aortic Disease 
  Chapter: Strategy for heparin-induced thrombocytopenia and anticoagulation replacement therapy. 
  Hall AC and Escobar MAEditors: S Zhou and A Estrera.Liaoning Science and Technology Publishing House2018
• Encyclopedia of Human Biology 
  Chapter: Hemophilia 
  Escobar, M.A., Nguyen T.T.Willey-Blackwell2014
• Textbook of Haemophilia 
  Chapter: Products used to treat haemophilia: Dosing. 
  Escobar M.A.Editors: Lee, K Hoots and E Berntop.Blackwell Publishing2014
• Hemophilia and Hemostasis: A Case-Based Approach to Management 
  Ma, DA., Roberts, HR., Escobar, MAWilley-BlackwellEdition Seco,2012
• Williams Hematology 
  Chapter: Hemophilia A and Hemophilia B 
  Roberts, H.R., Key, N., Escobar, M.A.Editors: Beutler E., et al..McGraw HillEdition Eigh,2010
• Textbook of Haemophilia 
  Chapter: Products used to treat haemophilia: Dosing 
  Escobar M.A.Editors: C Lee, K Hoots and E Berntop.Blackwell Publishing2010
• Evidence- based Hematology 
  Chapter: Diagnosis and management of acquired bleeding disorders: Vitamin K antagonists. 
  Escobar, M.A.Editors: Crowther, M., Ginsberg, J., et al..Blackwell Publishing2008
• Lange Q&A. USMLE Step 3 Fifth Edition 
  Brisco, A.D.; Escobar, MA (Contributor)McGraw-HillEdition 5th,2007
• Lange Q&A. USMLE Step 3 Fourth Edition 
  Brisco, A.D.; Escobar, MA (Contributor)McGraw-HillEdition 4th,2007
• PocketMedicine/Internal Medicine 
  Chapter: Thrombophilia. 
  Escobar, M.A., Roberts, H.R. and Ma, A.Editors: B.F. Scharschmidt.2007
• Hemostasis and Thrombosis: basic principles and clinical practice 
  Chapter: Inherited disorders of prothrombin conversion. 
  Roberts, H.R., Escobar, M.A.Editors: Colman RW, Hirsh J, Marder VJ et al..Lippincott Williams & WilkinsEdition Fift,2006
• Textbook of Haemophilia 
  Escobar M.A.Editors: C Lee, K Hoots and E Berntop.Blackwell Publishing2005
• Hematology: Basic Principles and Practice. 
  Chapter: Other clotting factor deficiencies. 
  Roberts, HR, Escobar, M.A.Editors: Hoffman R., et al..Churchill LivingstoneEdition Four,2005
• Thrombosis and Hemorrhage. 
  Chapter: Other coagulation factor deficiencies. 
  Roberts, H.R. and Escobar, M.A.Editors: J Loscalzo and AI Schafer.Williams & Wilkins CompanyEdition Thir,2002
• Pocket Medicine/Internal Medicine 
  Chapter: Thrombophilia. 
  Escobar, M.A., Roberts, H.R. and Ma, A.Editors: B.F. Scharschmidt.2002
• Hemofilia 
  Chapter: Concentrados purificados en el tratamiento de la hemofilia. 
  Page 389 - 396Escobar, M.A.Editors: CM Murillo, et al..Editorial Prado, S.A.2001
• Join now to see all

Abstracts/Posters

• The Dendritic Cell HLA-Class-II/Therapeutic Factor VIII (FVIII) Peptidome Is Influenced in Unanticipated Ways By the B-Domain of FVIII and the FVIII Chaperon Protein, ...
  Miguel A. Escobar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• On the Role of F8 Sequence Mismatch and Class-II Human Leukocyte Antigen Binding in the Development of Neutralizing Antibodies (Inhibitors) Directed Against Therapeuti...
  Miguel A. Escobar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Chronic Kidney Disease in the U.S. Hemophilia Population: A Cohort Study.
  Sood SL, Cheng D, Shapiro AD, Kessler CM,Key NS, Quon DV, Eyster E, Manco-Johnson MJ, Kempton CL,Cuker A, Ragni MV, Gill JC, Kuriakose P, Drygalski A, Kouides PA, Esco..., American Society of Hematology Annual meeting, San Diego, CA, 1/1/2018
• Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from 2 Clinical Trials).
  P Chowdary, L Poulsen, M Escobar, S Kearney, et al., American Society of Hematology Annual meeting, San Diego, CA, 1/1/2018
• Efficacy of on-demand treatment of bleeding episodes in hemophilia B patients with extended half-life N9-GP in pivotal trials: an in-depth analysis of treatment.
  Escobar M, Walsh C, Cooper D, Young G, National Hemophilia Foundation Meeting, 1/1/2018
• Coagulation Factor Use Evaluation at an Academic Medical Center.
  Grego AR, Okuboyejo J, Escobar M, Academy of Managed Care Pharmacy Meeting (AMCP), 1/1/2018
• Pharmaco-economic analysis of direct thrombin inhibitors using IgG Specific ELISA antibodies in suspected heparin induced thrombocytopenia.
  Samuel S, McGuire MF, Cortes J, Weeks P, Brown RS, Nguyen A, Escobar M, THSNA, 1/1/2018
• Pharmacoeconomic analysis of direct thrombin inhibitors using polyspecific ELISA antibodies in suspected heparin induced thrombocytopenia.
  Samuel S , McGuire MF, Cortes J, Weeks P, Brown RS, Nguyen A, Escobar M, Thrombosis & Hemostasis Societies of North America (THSNA), 1/1/2018
• Comparison of rFIX utilization and bleed rates in US hemophilia B patients on rIX-FP and their prior rFIX drug.
  Escobar M, Leissinger C, Yan S, Maro G, Krishnarajah G, Res Prac Thromb Haemost, 1/1/2018
• Chronic Kidney Disease in the U.S. Hemophilia Population: A Cohort Study.
  Sood SL, Cheng D, Shapiro AD, Kessler CM,Key NS, Quon DV, Eyster E, Manco-Johnson MJ, Kempton CL,Cuker A, Ragni MV, Gill JC, Kuriakose P, Drygalski A, Kouides PA, Esco..., THSNA, 1/1/2018
• Safety and efficacy of N9-GP, a recombinant glycoPEGylated factor IX with extended half-life, in US vs global patients with hemophilia B: results from the paradigm� cl...
  Young G, Lentz SR, Kearney S, Escobar M, Seremetis S, Cooper DL, Walsh C, THSNA, 1/1/2018
• Low dose 4-factor Prothrombin Complex Concentrate in reversal of Xa Inhibitors in a Neuro ICU.
  AllisonT, Hartman H, Gass J, Lin PJ, Chong K, Choi HA and Escobar M', Society of Critical Care Medicine annual Congress� Texas Chapter. Winner of the Alan I. Fields Award; Critical Care Congress, Honolulu, HI, 2016, 1/1/2017
• Prophylaxis with rIX-FP reduces consumption compared with previous FIX in both adult and pediatric patients.
  M Escobar, E Santagostino, C Leissinger, A Shapiro, J Oldenburg, B Pan-Petesch, Wilfried Seifert, the PROLONG-9FP Investigators, XXVI Congress of the International Society of Thrombosis and Haemostasis; Res Prac Thromb Haemost, Berlin, Germany, 1/1/2017
• Prediction of outcome in acquired hemophilia A.
  Escobar M, Donnachie E, XXVI Congress of the International Society of Thrombosis and Haemostasis, Berlin, Germany, 1/1/2017
• Characterization of the HLA-class-II (HLAcII)/Therapeutic Factor VIII (FVIII)-Derived Peptidome by FVIII Domain and HLAcII Isomer.
  Almeida M, Diego VP, Luu BW, Hofmann M, Garcia-Hern�ndez A, Peralta J, Curran J, Escobar M, et al., XXVI Congress of the International Society of Thrombosis and Haemostasis, Berlin, Germany, 1/1/2017
• Consumption of rVIII-SingleChain during prophylaxis in adult, adolescent and pediatric patients.
  Pabinger i, Fischer K, Gill J, Santagostino E, Boggio L, Escobar M and Mahlangu J, XXVI Congress of the International Society of Thrombosis and Haemostasis, Berlin, Germany, 1/1/2017
• A phase 1/2a, open-label, multicenter, dose escalation study to assess the safety, pharmacokinetics and pharmacodynamics profile of a long-acting recombinant factor VI...
  Young G, Quon DV, Escobar MA, Boggio LN, et al., XXV-I Congress of the International Society of Thrombosis and Haemostasis, Berlin, Germany, 1/1/2017
• La profilaxis con rIX-FP reduce el consumo en comparaci�n con el concentrado de FIX anterior en pacientes adultos y pedi�tricos.
  Spanish Hemophilia Society Meeting, 1/1/2017
• Characterization of the HLA-class-II (HLAcII)/Therapeutic Factor VIII (FVIII)-Derived Peptidome by FVIII Domain and HLAcII Isomer.
  Almeida M, Diego VP, Luu BW, Hofmann M, Garcia-Hern�ndez A, Peralta J, Curran J, Escobar M, et al., American Society of Hematology Annual meeting, Atlanta, GA, 1/1/2017
• Once-weekly prophylaxis with GlycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: safety and efficacy results from a randomized phase 3 trial (pathf...
  Curry N, Albayrak C, Escobar M, Holme PA, Kearnev S, et al., XXVI Congress of the International Society of Thrombosis and Haemostasis, Berlin, Germany, 1/1/2017
• Anti-FVIII IgG1 titers correlate with Bethesda levels in patients with acquired hemophilia.
  Escobar MA, Smith KC, Donnachie E, XXXII International Congress of the World Federation of Hemophilia, Orlando, FL, 1/1/2016
• Collecting clinical data through a care management assessment form during telephone patient encounters: A study among patients of the Gulf States Hemophilia and Thromb...
  Gustafson S, Lee M, Gonzaga C, and Escobar MA, XXXII International Congress of the World Federation of Hemophilia, Orlando, FL, 1/1/2016
• Genetic variant analysis in children and adults with hemophilia: experience from a large hemophilia center in the US.
  Lemons J, Brown D, Cantini M, Cannon K, Rodriguez N, Nguyen T, and Escobar M, XXXII International Congress of the World Federation of Hemophilia, Orlando, FL, 1/1/2016
• Prophylactic Efficacy of nonacog beta pegol once weekly in adult and pediatric patients with hemophilia B: a pooled analysis.
  Escobar M, Young G, Oldenburg J, Mahlangu J, et al., Thrombosis and Hemostasis Summit of North America (THSNA) Meeting, Chicago, IL, 1/1/2016
• Update on a phase � open-label trial of BAX 335, an adeno-associated virus 8 (AAV8) vector-based gene therapy program for hemophilia B.
  Monahan P, Walsh C, Konkle B, Powell J, Josephson N, Escobar M., et al., National Hemophilia Foundation 67th Annual Meeting, Dallas, TX, 1/1/2015
• Peri-operative haemostatic management of major orthopaedic surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX: results from the paradigm�3 ...
  Escobar M, Colberg T, Karim F, Caliskan U, et al., XIV International Musculoskeletal Congress WFH, Belfast, Ireland, 1/1/2015
• Perioperative hemostatic management of major surgery in hemophilia B with long-acting recombinant glycopegylated factor IX: results from the paradigm 3 clinical trial.
  Escobar M, Colberg T, Karim F, Caliskan U, Chowdary P, et al., XXV Congress of the International Society of Thrombosis and Haemostasis, Toronto, Canada, 1/1/2015
• Efficacy and safety of pdFX, a new high-purity factor X concentrate, in patients with mild to severe hereditary factor X deficiency undergoing surgery.
  Escobar M, Auerswald G, Austin S, Huang JN, Norton M, Millar C, National Hemophilia Foundation Meeting, Dallas, TX, 1/1/2015
• Experience of FACTOR X, a New High Purity Factor X Concentrate in Subjects with Factor X Deficiency Undergoing Surgery.
  Escobar M, Auerswald G, Austin S, et al., Hemostasis & Thrombosis Research Meeting, New Orleans, LA, 1/1/2015
• Comparison of different coagulation assays for the management of acquired hemophilia.
  Escobar M and Donnachie E, XXV Congress of the International Society of Thrombosis and Haemostasis, Toronto, Canada, 1/1/2015
• Mild hemophilia A complicated by inhibitor after surgery and factor replacement therapy.
  Escobar M, Chandra S, Wilson E, Chong K, XXV Congress of the International Society of Thrombosis and Haemostasis, Toronto, Canada, 1/1/2015
• BAY 81-8973: Safety Observations in Clinical Trials in Adults, Adolescents, and Children with Severe Hemophilia A.
  Escobar M, Obzut D, Humpries TJ, Afonja O, Detering E, National Hemophilia Foundation Meeting, Dallas, TX, 1/1/2015
• A Method for Deriving Pharmacokinetic Constants for Factor VIII and IX from Limited Blood Sampling.
  Escobar M, Bond D, Cantini M, Cannon C, American Society of Hematology Annual Meeting, Orlando, FL, 1/1/2015
• Safety and Efficacy of Recombinant Factor VIIa (rFVIIa) in Congenital Hemophilia with Inhibitors (CHwI) in the Home Treatment Setting: Systematic Review of Clinical St...
  Young G, Escobar M, Pipe S, Lenz S, Cooper D, American Society of Hematology Annual Meeting, Orlando, FL, 1/1/2015
• Assay Management for the Treatment of Hemophilia A and B: Experience from the Gulf States Pharmacy (GSP).
  Khleif A, Gustafson S, Lee M, Escobar MA, XXXI International Congress of the World Federation of Hemophilia, Melbourne, Australia, 1/1/2014
• A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population.
  Sood SL, Cheng D, Shapiro A, Kessler C, Key N, Quon D, Eyster E, Escobar M, et al., American Society of Hematology Annual Meeting, 1/1/2014
• Antifactor Xa Levels versus Activated Partial Thromboplastin Time for Monitoring Unfractionated Heparin. Which One to Believe? A Pilot Study.
  Samuel S., Allison TA., Yau G., Sharaf S., Mckaig N.,Ranjbar G., Lee K., Nguyen A., Choi HA., Escobar M, 12th Annual Neurocritical Care Society Meeting, Seattle, WA, 1/1/2014
• Safety and efficacy of a new high purity factor X concentrate in subjects with factor X deficiency undergoing surgery.
  Escobar M., Austin S., Auerswald G., Millar C., MacDonald S., orton M., and Aldwinckle T, XXXI International Congress of the World Federation of Hemophilia, Melbourne, Australia, 1/1/2014
• Factor Assistance Program Utilization: A Follow-Up Study among Patients Attending the Gulf States Hemophilia and Thrombophilia Center (GSHTC) in Houston, Texas Between...
  Khleif A, Gustafson S, Escobar MA, XXXI International Congress of the World Federation of Hemophilia, Melbourne, Australia, 1/1/2014
• Knowledge of Disease and Treatment Understanding among Patients with Hemophilia: Interim Results among Patients Attending the Gulf States Hemophilia and Thrombophilia ...
  Gustafson S, Khleif A, Escobar MA, XXXI International Congress of the World Federation of Hemophilia, Melbourne, Australia, 1/1/2014
• Treatment characteristics and associated costs of factor replacement and immunosuppressive therapy among patients with acquired hemophilia A.
  Escobar, MA, Chong, K. and Kheif, A, XXIV Congress of the International Society of Thrombosis and Haemostasis, Amsterdam, Netherlands, 1/1/2013
• Biomedical Analytics Approach Suggests a Role for TNF Superfamily Signaling In Acquired Hemophilia Patients Who Do Not Respond to Rituximab Treatment.
  Smith, K., Escobar, M.A., Donnachie, E, American Society of Hematology Meeting, New Orleans, LA, 1/1/2013
• Early cytokine secretion may predict response to treatment in acquired hemophilia.
  Escobar, MA, Csencsits-Smith. K., Donnachie, E., XXIV Congress of the International Society of Thrombosis and Haemostasis, Amsterdam, Netherlands, 1/1/2013
• Off-label use of recombinant factor VIIa: results from a 10-year university hospital study.
  Escobar, MA, Chong, K. and Kheif, A., XXIV Congress of the International Society of Thrombosis and Haemostasis, Amsterdam, Netherlands, 1/1/2013
• Adherence to Prophylaxis Treatment Regimens among Persons with Severe Hemophilia A and B: Results from a 1-Year, Single Institution Study.
  Khleif, A, Rodriguez, N., Nguyen, T., Brown D., and Escobar, MA, XXX International Congress of the World Federation of Hemophilia, Haemophilia, Paris, France, 1/1/2012
• �Pharmacokinetic behavior of IB1001, an investigational recombinant Factor IX, in patients with Hemophilia B: repeat pharmacokinetic study and sialylation analysis�
  Martinovich,U., Lubetsky, A., Shapiro, A., Quon, D., Escobar, M, Kempton, C., et al., 53rd Annual Meeting of the American Society of Hematology, San Diego, CA, 1/1/2011
• harmacokinetics of IB1001, a new recombinant Factor IX.
  Martinowitz, U., Shapiro, A., Quon, D., Escobar, M., et.al., Haemophilia, 1/1/2011
• Novel Tolerogen Prevents Inhibitor Formation in a Mouse Model of Hemophilia A.
  Nguyen,T, Donnachie,E., Borck,M., Pascual,D., Escobar,M., Smith,K., American Society of Pediatric Hematology/Oncology 23rd Annual Meeting; Pediatric Blood and Cancer, 1/1/2010
• Effects of a novel mucosal tolerogen on critical T cell cytokine secretion and development of anti-FVIII inhibitor antibody in a mouse model of hemophilia A.
  Csencsits-Smith. K., Nguyen, T.T., Donnachie,E., Borck,M., Escobar, M., et.al., J. Immunol., 1/1/2010
• Revisiting the mostly-conserved CD4 binding site core regi�n as an HIV vaccine target.
  Paul, S., Planque, S., Nishiyama, Y., Nishiyama, Y., Ghosh, D., Escobar, M.A., and Hanson, C., AIDS Vaccine Conference, 1/1/2010
• A Protease Resistant Factor VIII Analog for Blockage of Inhibitory Antibodies.
  Planque, S., Escobar, M., Nishiyama, Y., and Paul, S., American Society of Hematology Annual Meeting; BLOOD, 1/1/2010
• Risk Factors for Inhibitor Development in Mild and Moderate Hemophilia A: A Case-Control Study.
  Kempton, C.L., Soucie, J.M., Miller, C.H., Hooper, C., Escobar, M.A., et.al., American Society of Hematology Annual Meeting, BLOOD, 1/1/2009
• Absence of Inhibitor Development in the Routine Clinical Use of Alphanate in Patients with Severe Hemophilia A: Results from a Long-Term Post-Marketing Surveillance St...
  Sexauer, C.L., Ayob, Y., Cantini,M., Escobar, M.A.; et.al., American Society of Hematology Annual Meeting, BLOOD, 1/1/2009
• Randomized, Controlled, Parallel, Prospective Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult Subjects Compared ...
  Laff, S.P., Manco-Johnson, M., Bernstein, J., Cohen, A., DiMichele, D., Escobar, M., et. al., National Hemophilia Foundation Meeting, 1/1/2009
• Recombinant Activated Factor VII for surgical evacuation of subdural hematoma in patients with coagulopathy.
  Havelli, H., Adejuwon, O., Escobar, M.A., Chong, K., Allison, TA., Stroke, 1/1/2009
• Establishment of a camp for children with bleeding disorders in a developing country.
  Diaz, E., Reyes, A., Murillo, A., Cantini, M., Kuebler, E., Escobar, M., XXVIII International Congress of the World Federation of Hemophilia, 1/1/2008
• Assessing Clinical and Demographic Trends in a US Hemophilia Treatment Center Population.
  Riley, L., Ullman, M., Sayre, D., Hoots, K., and Escobar. M., XXVIII International Congress of the World Federation of Hemophilia, 1/1/2008
• Pretreatment of CD138- B Lymphocytes with a Covalent Reactive Antigen Analog to Factor VIII Reduces Antibody Production in response to FVIII.
  Smith, K.C., Planque, S., Nishiyama, Y., Taguchi, H., Escobar, M., and Paul, S., 94th Annual Meeting, The American Association of Immunologists, Miami, FL, 1/18/2007
• A Covalent Reactive Antigen Analog to Factor VIII Reduces Antibody Production in Memory B Cells After Re-stimulation With FVIII.
  Smith, K.C., Planque, S., Nishiyama, Y., Escobar, M., Paul, S., XXI Congress of the International Society of Haemostasis and Thrombosis; J Thromb Haemost, Geneva, Switzerland, 1/6/2007
• Failure of Immune Tolerance Induction in Haemophilia B Patients with C, T 6460 Nonsense Mutation.
  Rodriguez, N.I., Hoots, W.K., Brown, D.L., Womack, M., Cantini, M., Escobar, M.A., J Thromb Haemost, 1/1/2007
• Sensitivity to Activated Protein C (APC) is Increased During the Secretory Phase of the Menstrual Cycle.
  Brown, D.L., Donnachie, E., Escobar, M., Rosas, P., Griffin, J., Hoots, W., J Thromb Haemost, 1/1/2007
• Rituximab as a Treatment Option for Acquired Inhibitors.
  Souza J.A., Escobar M.A., Blood, 1/1/2006
• Naturally Occurring Catalytic IgAs: Protective Anti-HIV Mediators?
  Planque, S,. Mitsuda, Y., Taguchi, H., Salas, M., Morris, MK., Nishiyama, Y., Kyle, R., Okhuysen, P., Escobar, MA., Hunter, R., Sheppard, HW., Hanson, C. and Paul S., Center for AIDS Research Retreat, Baylor College of Medicine, Houston, TX, 1/1/2006
• Recombinant factor VIIa partially reverses the effects of anticoagulants and antiplatelet agents on thrombin generation and thromboelastography.
  Abdullatif ML, Donnachie E., Escobar M.A., Blood, 1/1/2005
• Trauma in a non-hemophilic individual.
  Escobar, M.A., Donnachie, E., Friedrich, U., Hedner, U., 8th Novo Nordisk Symposium on Haemostasis Management, Copengahen, Denmark, 1/1/2005
• Patient safety evaluation in a major trauma clinical trial evaluating a new drug.
  Champion H.R., Weiskopf, R., Fingerhut, A., Escobar, M.A., American Association for the surgery of trauma annual meeting, 1/1/2004
• Experience with the �off-label� use of recombinant factor VIIa in a university hospital.
  Escobar, M.A., Chong, K., Hoots, W.K., Blood, 1/1/2004
• Irreversible blockade of factor VIII antibodies.
  Planque, S., Escobar, M.A., Taguchi, H., Karle, S., Nishiyama, Y., Donacchie, E., Paul, S., Blood, 1/1/2004
• Elevated IgE associated with factor VIII inhibitor levels in patients with hemophilia A.
  Salicru A.N., Escobar M.A., Hoots W.K., Marshall G.D., The Journal of Allergy and Clinical Immunology, 1/1/2004
• Congenital factor VII deficiency and thrombosis. Description of a novel mutation.
  Escobar M, Ulmasov, B., Kuppuswamy, M.N., Bajaj, M.S., Fisher, L, Bajaj, S.P., Journal of Thrombosis and Haemostasis, 1/1/2003
• Mutation analysis and HLA genotype in patients with inhibitors and hemophilia A.
  Escobar, M., White G.C., Journal of Thrombosis and Haemostasis, 1/1/2003
• Elevated IgE Associated with Factor VIII Inhibitor Levels in Patients with Hemophilia A.
  Escobar M.A., Salicru A.N., Hoots W.K., Marshall G.D., Blood, 1/1/2003
• Successful treatment of an autoantibody in congenital hemophilia with Rituximab.
  Escobar, M.A., Kempton, C, Ma, A., Blood, 1/1/2002
• General Clinical Experience with NovoSeven including Experience with High Bolus Dosing.
  Escobar, M.A., World Federation of Hemophilia, Seville, Spain, 1/1/2002
• Experience with the Use of Recombinant Factor VIIa in a University Hospital.
  Escobar, M.A., Harvey, R.D., Blood, 1/1/2001
• Dose response of Recombinant Factor VIIa in Patients with Hemophilia and Liver Disease.
  Escobar, M.A., Melton, L.G., Thompson, C.N., Gabriel, D.A., Blood, 1/1/2001
• Advances in Gene Therapy.
  Escobar, M.A., XVII International Congress on Hemostasis and Thrombosis, CLAHT, Mexico City, Mexico, 1/1/2001
• Vascular Dementia Among Patients with ITP (Immune Thrombocytopenic Purpura) and Risk Factors.
  Ahn Y.S., Horstman L.L., Jy W., Jimenez, J.J., Cui Y., Escobar M.A. and Bowen B., Blood, 1/1/2000
• Expression of the Second Kunitz Domain of Human Tissue Factor Pathway Inhibitor by a Yeast Expression System.
  Escobar, M.A., Chang, JY, Roberts, HR and Monroe, DM, Thrombosis and Haemostasis, 1/1/1999
• Clinical Experience with the use of recombinant VIIa.
  Escobar, M.A., Roberts, HR, XVI International Congress on Haemostasis and Thrombosis, CLAHT, Lima, Peru, 1/1/1999
• Chronic platelet activation and progressive vascular dementia in patients with Immune Thrombocytopenic Purpura (ITP).
  Ahn Y.S., Cui Y., Horstman L.L., Jy W., Escobar M.A. and Bowen B., 1st International Congress on vascular dementia, Geneva, Switzerland, 1/1/1999
• New Concepts in Coagulation.
  Roberts, H.R., Escobar, M.A., Brinkhous, K., XV International Congress on Haemostasis and Thrombosis, CLAHT, Santo Domingo, Dominican Republic, 1/1/1997
• �New Concepts in Coagulation�
  Escobar, MA, XV International Congress on Haemostasis and Thrombosis, CLAHT, Santo Domingo, Dominican Republic, 1/1/1997
• �Recombinant Factor VIIa�
  Escobar, MA, XV International Congress on Haemostasis and Thrombosis, CLAHT, Santo Domingo, Dominican Republic, 1/1/1997
• Recombinant Factor VIIa.
  Roberts, H.R., Escobar, M.A., Brinkhous, K., XV International Congress on Haemostasis and Thrombosis, CLAHT, Santo Domingo, Dominican Republic, 1/1/1997
• Extended dosing intervals with RIX-FP prophylaxis reduces factor IX consumption compared with previous prophylaxis regimens in clinical studies of haemophilia B patients.
  Pan-Petesch B, Santagostino E, Leissinger C, Shapiro A, Oldenburg J, Seifert W, Escobar M and the PROLONG-9FP Investigators, EAHAD 2018Haemophilia P062
• Join now to see all

Lectures

• Consistency of Dosing of Turoctocog Alfa Pegol (N8-GP) throughout the Pathfinder Clinical Trials: Implications for Recommendations for Effective Prophylaxis, Bleed Res... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• New Therapeutic Options in Hemophilia 
  Mexico City, MX - 1/1/2018
• New Treatments in Hemophilia, including gene therapy 
  Nuevo Vallarta, Mexico - 1/1/2018
• How can we Decrease the Risk of inhibitors in Hemophilia 
  Nuevo Vallarta, Mexico - 1/1/2018
• �New Treatment Strategies for the Treatment of Bleeding Disorders� 
  University of Texas Health Science Center at Houston - 1/1/2017
• �New Treatment Strategies for Hemophilia Management� 
  Republica Dominicana - 1/1/2017
• �Standard of Care for Hemophilia in the Developed World�. 
  Republica Dominicana - 1/1/2017
• �Prophylaxis in hemophilia. New therapeutic options.� 
  Chicago, IL - 1/1/2015
• �Treatment Options for prophylaxis in hemophilia�. 
  Texas Children's Hospital, Houston, TX - 1/1/2015
• �DIC, Bleeding Disorders and Coagulopathy�. 
  Houston, TX - 1/1/2015
• �One in a Million: Rare Bleeding Disorders� 
  Dallas, TX - 1/1/2015
• �Rare Bleeding Disorders� 
  Dallas, TX - 1/1/2015
• �Management of Comorbidities in Hemophilia and vonWillebrand Disease� 
  Sao Paulo, Brazil - 1/1/2015
• �New Methods to Predict the Immunogenicity of Therapeutic Coagulation Proteins�. 
  Bethesda, MD - 1/1/2015
• �Management of other comorbidities in hemophilia� 
  Caracas, Venezuela - 1/1/2015
• �Appropriate Use of Blood Components in a Modern Acute Care Hospital� 
  Houston, TX - 1/1/2014
• �Blood Utilization Program� 
  Memorial Hermann Hospital, TMC - 1/1/2014
• �Hemophilia Care in Developed Countries�. 
  Panama City, Panama - 1/1/2014
• �Ask the Experts: inhibitors in Hemophilia� 
  Washington, DC - 1/1/2014
• �Update on Coagulation Assays. More Than Just PT/PTT� 
  Cali, Colombia - 1/1/2014
• �Emerging Coagulation Factors for Hemophilia� 
  Cali, Colombia - 1/1/2014
• �New Oral Anticoagulants� 
  University of Texas Health Science Center at Houston - 1/1/2013
• �Prophylaxis in Hemophilia�. 
  Mexico City - 1/1/2013
• �Management of Patients with inhibitors� 
  1/1/2013
• �The Obesity Epidemic: Weight Management, Bariatric Surgery & Related Cosmetic Surgery” 
  Anaheim, CA - 1/1/2013
• �Aging: Comorbidities and Bleeding Disorders" 
  Anaheim, CA - 1/1/2013
• �Inhibitors in Hemophilia A and B. Acute Treatment and Immune Tolerance is a good solution?� 
  Cancun, Mexico - 1/1/2013
• �Differences Between Hemophilia A and B�. 
  Cancun, Mexico - 1/1/2013
• �New Concepts in Coagulation� 
  University of Texas Health Science Center at Houston - 1/1/2012
• �Sugar and Spice and not Everything Nice: New Anticoagulants" 
  University of Texas Health Science Center at Houston - 1/1/2012
• �Management of Patients with Rare Bleeding Disorders.� 
  Houston, TX - 1/1/2012
• �New Anticoagulants� 
  Medellin, Colombia - 1/1/2012
• "Sugar and Spice and not Everything Nice: Alternative Medicine and Bleeding Disorders" 
  Orlando, FL - 1/1/2012
• �Heparin Induced Thrombocytopenia Diagnosis and Management� 
  University of Texas Health Science Center at Houston - 1/1/2011
• �Hemophilia and Aging: Challenges and Implications for Future Care�. 
  University of Texas Health Science Center at Houston - 1/1/2011
• �Transition of hemophilia patients to the adult world-what are the challenges?�. 
  Houston, TX - 1/1/2011
• �Immune Tolerance Induction in Hemophilia� 
  Buenos Aires, Argentina - 1/1/2011
• �Aging in Hemophilia� 
  Buenos Aires, Argentina - 1/1/2011
• �Immune Tolerance in Hemophilia� 
  San Pedro Sula, Honduras - 1/1/2011
• �Multidisciplinary Management of Hemophilia� 
  San Pedro Sula, Honduras - 1/1/2011
• �Prophylaxis in Hemophilia� 
  Mexico City - 1/1/2011
• �Heparin Induced Thrombocytopenia� 
  University of Texas Health Science Center at Houston - 1/1/2010
• �Hemostasis in Cardiovascular Surgery� 
  Houston, TX - 1/1/2010
• �Hemophilia and Inhibitors� 
  Hospital Pediatrico Benjamin Bloom, El Salvador - 1/1/2010
• �Venous Thromboembolism� 
  University of Texas Health Science Center at Houston - 1/1/2009
• �Factor Replacement in Bleeding Disorders: What is the best dose and duration of therapy.� 
  Houston, TX - 1/1/2009
• �El uso del Factor VIIa recombinante en condiciones diferentes a la hemofilia." 
  Instituto de Investigaciones Fundacion Universitaria Sanitas. Bogota, Colombia - 1/1/2009
• �Review on Bleeding Disorders�. 
  El Salvador - 1/1/2009
• �New Concepts in Hemostasis�. 
  Hospital Pediatrico Benjamin Bloom, El Salvador - 1/1/2009
• Acquired Haemophilia: Treatment Options 
  Kuala Lumpur, Malaysia - 1/1/2009
• Management of Mild to Moderate Bleeding with Inhibitors 
  Kuala Lumpur, Malaysia - 1/1/2009
• �Reversal of anticoagulants� 
  Landshut, Germany - 1/1/2009
• �Acquired Hemophilia� 
  La Habana, Cuba - 1/1/2009
• �Plasmatic Concentrates vs Recombinant in Inhibitors Development� 
  La Habana, Cuba - 1/1/2009
• �Diagnostico y tratamiento del paciente que desarrolla inhibidor�. 
  Monterrey, Mexico - 1/1/2009
• �Health Economics: A review from the Clinician�s Perspective�. 
  Prague, Czech Republic - 1/1/2009
• �Bleeding disorders 101 or Understanding Your Diagnosis� 
  San Francisco, CA - 1/1/2009
• �Comprehensive care from a cultural perspective: The Latino Patient� 
  Taipei, Taiwan - 1/1/2009
• �Management and Monitoring of Oral Anticoagulants� 
  University of Texas Health Science Center at Houston - 1/1/2008
• �Challenges in the Therapeutic use of Hemostatic Agents in the Acute Care Setting." 
  St. Christopher�s Hospital for Children, Philadelphia, PA - 1/1/2008
• �Inhibitors in hemophilia� 
  Panama City, Panama - 1/1/2008
• �Prophylaxis in patient with hemophilia� 
  Panama City, Panama - 1/1/2008
• �Management of critical bleeding in patients without congenital hemophilia�. 
  Panama City, Panama - 1/1/2008
• �Cuando utilizar los nuevos anticoagulantes.� 
  Instituto de Investigaciones Fundacion Universitaria Sanitas. Bogota, Colombia - 1/1/2008
• �Challenges in the Use of Recombinant FVIIa" 
  University of Texas Health Science Center at Houston - 1/1/2007
• �Transfusions in children� 
  Ciudad Juarez, Mexico - 1/1/2007
• �Managing/Monitoring Bleeding Complications� 
  Franklin, TN - 1/1/2007
• �Acquired Hemophilia � a diagnostic and therapeutic challenge�. 
  Punta del Este, Uruguay - 1/1/2007
• �Management of Critical bleeding�. 
  San Jose, Costa Rica - 1/1/2007
• �Treatment of Hemophilia: the benefits of recombinant products�. 
  Acapulco, Mexico - 1/1/2007
• �Viral Risks and Thrombotic Complications of Coagulation factors� 
  Universidad Latinoamericana de la Hemofilia, Buenos Aires, Argentina - 1/1/2007
• �Treatment of Hemorrhagic Episodes in Patients with Hemophilia� 
  Universidad Latinoamericana de la Hemofilia, Buenos Aires, Argentina - 1/1/2007
• �New Approaches in the Diagnosis and Treatment of Acquired Hemophilia�. 
  Taipei, Taiwan - 1/1/2007
• �Past, Present and Future: GSHTC and Hospital Infantil Benjamin Bloom Twining Program�. 
  El Salvador - 1/1/2007
• �Recombinant Factor VIIa� 
  University of Texas Health Science Center at Houston - 1/1/2006
• �Nuevos conceptos de coagulaci�n� 
  Quito, Ecuador - 1/1/2006
• �Directrices de la FMH para el tratamiento del paciente con hemofilia� 
  Quito, Ecuador - 1/1/2006
• �Transfusiones: Riesgos y contaminacion� 
  Quito, Ecuador - 1/1/2006
• �Inhibidores: Aspectos Generales� 
  Quito, Ecuador - 1/1/2006
• �Diagnostico y manejo de portadoras" 
  Quito, Ecuador - 1/1/2006
• �The role of Recombinant FVIIa in Critical Bleeding�. 
  Caracas, Venezuela - 1/1/2006
• "The role of Recombinant FVIIa in Critical Bleeding�. 
  Barquisimeto, Venezuela - 1/1/2006
• �Making Treatment Choices in Hemophilia� 
  Mt. Sinai Medical Center, New York, NY - 1/1/2006
• �Success Through the Years in Hemophilia� 
  El Paso, TX - 1/1/2006
• �New Concepts of Coagulation� 
  University of Texas Health Science Center at Houston - 1/1/2005
• �Congenital Hemophilia and Inhibitors� 
  Moffitt Cancer Center, Tampa, Florida - 1/1/2005
• �Off-Label use of rFVIIa� 
  Denver, CO - 1/1/2005
• �Treatment Strategies for Rare Congenital Bleeding Disorders� 
  Washington, DC - 1/1/2005
• �Fisiologia de la coagulacion, nuevos adelantos y fusion de teorias� 
  Bogota, Colombia - 1/1/2005
• �Manejo de Inhibidores en el hemofilico� 
  Bogota, Colombia - 1/1/2005
• �Acquired Inhibitors to Factor VIII� 
  Rio de Janeiro - 1/1/2005
• �Recombinant Factor VIIa in the Treatment of Glanzmann Thrombastenia and Congenital Factor VII Deficiency� 
  Rio de Janeiro - 1/1/2005
• "Prophylaxis in Patients with Inhibitors� 
  Rio de Janeiro - 1/1/2005
• �Inhibitors in Hemophila� 
  Chile - 1/1/2005
• �Remodeling the Coagulation Cascade � Simplifying the Complex� 
  University of Texas Health Science Center at Houston - 1/1/2004
• �Update on Hemophilia and Factor VIIa Therapy� 
  University of Texas Health Science Center at Houston - 1/1/2004
• �Hematologic Emergencies� 
  University of Texas Health Science Center at Houston - 1/1/2004
• �Medical and Surgical Bleeding� 
  Bryce Hospital, Tuscaloosa, AL - 1/1/2004
• �Surgical Bleeding� 
  Yampa Valley Medical Center, Steamboat Springs, CO - 1/1/2004
• Join now to see all